Should You Buy Magenta Therapeutics Inc (MGTA) in Biotechnology Industry?

Monday, May 15, 2023 11:51 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Magenta Therapeutics Inc (MGTA) in Biotechnology Industry?

A rating of 87 puts Magenta Therapeutics Inc (MGTA) near the top of the Biotechnology industry according to InvestorsObserver. Magenta Therapeutics Inc's score of 87 means it scores higher than 87% of stocks in the industry. Magenta Therapeutics Inc also received an overall rating of 72, putting it above 72% of all stocks. Biotechnology is ranked 22 out of the 148 industries.

MGTA has an Overall Score of 72. Find out what this means to you and get the rest of the rankings on MGTA!

See Full MGTA Report

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Magenta Therapeutics Inc Stock Today?

Magenta Therapeutics Inc (MGTA) stock is higher by 10.35% while the S&P 500 is down 0% as of 11:47 AM on Monday, May 15. MGTA is higher by $0.07 from the previous closing price of $0.63 on volume of 155,406 shares. Over the past year the S&P 500 is higher by 2.90% while MGTA is down -36.36%. MGTA lost -$1.29 per share the over the last 12 months. Click Here to get the full Stock Report for Magenta Therapeutics Inc stock.